Alexander Zehnder, CureVac CEO (via website)

Cure­Vac claims de­lay in Ger­man court over al­leged in­fringe­ment of its Covid-19 vac­cine by BioN­Tech a sign in its fa­vor

Cure­Vac is ex­pect­ing good news in its patent in­fringe­ment cas­es for com­po­nents of its Covid-19 vac­cine against Pfiz­er part­ner BioN­Tech in Ger­many af­ter a court post­poned pro­ceed­ings on four cas­es, the com­pa­ny an­nounced Thurs­day.

Cure­Vac said that courts in Ger­many on­ly sus­pend pro­ceed­ings if they be­lieve there has been in­fringe­ment on patent­ed prop­er­ty.

“Giv­en the par­tic­u­lar­i­ties of Ger­man patent law, where patent in­fringe­ment and va­lid­i­ty are ad­ju­di­cat­ed by sep­a­rate pro­ceed­ings, the sus­pen­sion of pro­ceed­ings un­til the va­lid­i­ty of in­tel­lec­tu­al prop­er­ty rights has been de­ter­mined was ex­pect­ed,” Cure­Vac CEO Alexan­der Zehn­der said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.